Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
0.646
+0.024 (3.78%)
At close: Jun 26, 2026, 4:00 PM EDT
0.638
-0.007 (-1.15%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Company Description
Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia.
The company’s product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters.
Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Todd Usen |
Contact Details
Address: 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 United States | |
| Phone | 949 348 1188 |
| Website | adagiomedical.com |
Stock Details
| Ticker Symbol | ADGM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002006986 |
| CUSIP Number | 00534B100 |
| ISIN Number | US00534B1008 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Todd Usen | Chief Executive Officer and Director |
| Deborah Kaster | Chief Financial Officer and Chief Business Officer |
| Antwan Gipson M.B.A. | Senior Vice President of Manufacturing and Operations |
| Dr. Alex Babkin Ph.D. | Chief Technical Officer |
| Nabil Jubran | Chief Compliance Officer |
| Ilya Grigorov | Vice President of Global Marketing and Product Management |
| Marie-Claude Jacques | Senior Vice President of Global Sales |
| Maryline Cullen | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 8-K | Current Report |
| May 21, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | 8-K | Current Report |